Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells

International Journal of Cancer

Volumn 73, Issue 5, 1997, Pages 663-669

  Garrity, Thomas ^a   Pandit, Rajiv ^a   Wright, Mark A ^b   Benefield, Janet ^a,b   Keni, Sarita ^a   Young, M Rita I ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; COLECALCIFEROL; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEM CELL FACTOR;

ANTIGEN PRESENTATION; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; DENDRITIC CELL; DRUG EFFECT; FLOW CYTOMETRY; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGY; LYMPHOCYTE COUNT; MONONUCLEAR CELL; PATHOLOGY; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA;

ANTIGEN PRESENTATION; ANTIGENS, CD34; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELLS, CULTURED; CHOLECALCIFEROL; DENDRITIC CELLS; FLOW CYTOMETRY; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HEAD AND NECK NEOPLASMS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE COUNT; STEM CELL FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 0031588347     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971127)73:5<663::AID-IJC9>3.0.CO;2-V     Document Type: Article

References (23)

1. + hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res., 55, 1099-1104 (1995).
2. + T-cells and process soluble antigen. J. Immunol., 155, 5427-5435 (1995).
3. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNFα. J. exp. Med., 184, 695-706 (1996a).
4. + hematopoietic progenitor cells. Blood, 87, 2376-2385 (1996b).
5. CLAYMAN, G.L., TAYLOR, D.L., LIU, F.J., LAVEDAN, P., SAVAGE, H.E. and SCHANTZ, S.P., Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells. Laryngoscope, 103, 299-307 (1993).
6. FLAMAND, V., SORNASSE, T., THIELEMANS, K., DEMANET, C., BAKKUS, M., BAZIN, H., TIELEMANS, F., LEO, O., URBAIN, J. and MOSER, M., Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. J. Immunol. 24, 605-610 (1994).
7. GIESELER, R.K., ROBER, R.A., KUHN, R., WEBER, K., OSBORN, M. and PETERS, J.H., Dendritic accessory cells derived from rat bone marrow precursors under chemically defined conditions in vitro belong to the myeloid lineage. Europ. J. Cell Biol., 54, 171-181 (1991).
8. GIROLOMONI, G. and RICCIARDI-CASTAGNOLI, P., Dendritic cells hold promise for immunotherapy. Immunol. Today, 18, 102-104 (1997).
9. GRABBE, S., BEISSERT, S., SCHWARZ, T. and GRANSTEIN, R.D., Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today, 16, 117-121 (1995).
10. HADDEN, J.W., ENDICOTT, J., BAEKEY, P., SKIPPER, P. and HADDEN, E.M., Interleukins and contrasuppression induce immune regression of head and neck cancer. Arch. Otolaryngol. Head Neck Surg., 120, 395-403 (1994).
11. HASSAN, H.T. and ZANDER, A., Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis [Abstract]. Acta Haematol., 95, 257-262 (1996).
12. KAFFENBERGER, W., HOLZER-MULLER, L., AUBERGER, T., CLASEN, B.P., HOHLMEIER, G. and VAN BEUNINGEN, D., An immunological outcome predictive score for head and neck carcinoma patients. Strahlentherapie Onkol., 171, 444-453 (1995).
13. RIEDL, E., STROBL, H., MAJDIC, O. and KNAPP, W. TGF-β1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. J. Immunol., 158, 1591-1597 (1997).
14. + hematopoietic progenitor cells. Blood, 87, 1292-1302 (1996).
15. SZABOLCS, P., AVIGAN, D., GEZELTER, S., CIOCON, D.H., MOORE, M.A.S., STEINMAN, R.M. and YOUNG, J.W., Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood, 87, 4520-4530 (1996).
16. 3-induced terminal monocytic differentiation of human leukemic cell lines. J. Immunol., 150, 2418-2430 (1993).
17. TJOA, B., ERICKSON, S., BARRBN, R., III, RAGDE, H., BOYNTON, A. and MURPHY, G., In vitro propagated dendritic cells from prostate cancer patients as component of prostate cancer immunotherapy. Prostate, 4, 63-69 (1995).
18. 3. Leukemia, 8, 266-273 (1994).
19. 3 differentially regulates activation of normal T-cells versus of tumor bearers through protein phosphatase-2A. Cancer Immunol. Immunother., 44, 97-102 (1997).
20. 3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. Cancer Lett., 104, 153-161 (1996a).
21. + cells in cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res., 1, 95-103 (1995).
22. YOUNG, M.R.I., WRIGHT, M.A., LOZANO, Y. MATTHEWS, J.P., BENEFIELD, J. and PRECHEL, M.M., Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int. J. Cancer. 67, 333-338 (1996b).
23. + natural suppressor cells. Int. J. Cancer, 74, 69-74 (1997).